Cai et al. (2020) hypothesized that hollow manganese Prussian white nanocapsules (HMPWCs) participated in the resistance to the harmful effects of tau by relieving neuronal inflammation, eliminating ROS, and inhibiting tau hyperphosphorylation. Targeting of astrocytic NRF2, a regulator of GSH synthesis, could be a potent therapeutic strategy in AD (Oksanen et al., 2019). Here, MAPT is linked to Alzheimer disease.